Alimera Sciences (NASDAQ:ALIM) Now Covered by StockNews.com

StockNews.com initiated coverage on shares of Alimera Sciences (NASDAQ:ALIM) in a research note published on Friday. The brokerage issued a hold rating on the biopharmaceutical company’s stock.

Other equities research analysts have also recently issued reports about the stock. Alliance Global Partners reaffirmed a neutral rating on shares of Alimera Sciences in a research report on Tuesday, June 25th. HC Wainwright cut shares of Alimera Sciences from a buy rating to a neutral rating and set a $6.00 price target on the stock. in a research report on Tuesday, June 25th. Finally, Maxim Group reissued a hold rating on shares of Alimera Sciences in a research report on Tuesday, June 25th.

Alimera Sciences Trading Up 0.7 %

ALIM opened at $5.60 on Friday. The stock has a market capitalization of $293.38 million, a P/E ratio of -3.57 and a beta of 1.28. Alimera Sciences has a 12 month low of $2.61 and a 12 month high of $5.65. The firm’s fifty day simple moving average is $3.88 and its 200 day simple moving average is $3.81. The company has a current ratio of 2.62, a quick ratio of 2.51 and a debt-to-equity ratio of 1.71.

Alimera Sciences (NASDAQ:ALIM) last posted its quarterly earnings data on Tuesday, May 14th. The biopharmaceutical company reported ($0.12) EPS for the quarter, missing the consensus estimate of ($0.04) by ($0.08). The company had revenue of $23.01 million during the quarter, compared to the consensus estimate of $23.72 million. Alimera Sciences had a negative net margin of 23.74% and a negative return on equity of 53.49%. During the same period in the prior year, the firm posted ($0.71) earnings per share. As a group, research analysts anticipate that Alimera Sciences will post -0.13 EPS for the current fiscal year.

Institutional Investors Weigh In On Alimera Sciences

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Stonepine Capital Management LLC raised its holdings in shares of Alimera Sciences by 0.4% in the 4th quarter. Stonepine Capital Management LLC now owns 3,999,459 shares of the biopharmaceutical company’s stock valued at $17,278,000 after purchasing an additional 15,773 shares during the period. Vanguard Group Inc. raised its holdings in shares of Alimera Sciences by 61.1% in the 1st quarter. Vanguard Group Inc. now owns 1,045,460 shares of the biopharmaceutical company’s stock valued at $4,077,000 after purchasing an additional 396,506 shares during the period. Ancora Advisors LLC bought a new stake in shares of Alimera Sciences in the 1st quarter valued at about $915,000. Hillsdale Investment Management Inc. bought a new stake in shares of Alimera Sciences in the 1st quarter valued at about $169,000. Finally, Fifth Lane Capital LP bought a new stake in shares of Alimera Sciences in the 1st quarter valued at about $83,000. 99.83% of the stock is owned by institutional investors.

About Alimera Sciences

Alimera Sciences, Inc, a pharmaceutical company, develops and commercializes prescription ophthalmic retinal pharmaceuticals. It operates through United States, International, and Operating Cost segments. The company offers ILUVIEN, a fluocinolone acetonide intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye (NIU-PS).